PHarmaceutical tech@2x
Diseases Cardiovascular

Sections

  • Clinical Trials
  • Supply Chain
  • Drug Development
  • Manufacturing
  • Diseases
    • Cardiovascular
    • Central Nervous System
    • Immunology
    • Infectious Diseases
    • Oncology
    • Respiratory

Most Read

  • AstraZeneca divests Atacand commercial rights to Cheplapharm
  • Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
  • AstraZeneca’s heart failure treatment Forxiga gets approval in Japan

Most Recent

deal

AstraZeneca divests Atacand commercial rights to Cheplapharm

05 Jan 2021
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Diseases Cardiovascular

Sections

  • Clinical Trials
  • Supply Chain
  • Drug Development
  • Manufacturing
  • Diseases
    • Cardiovascular
    • Central Nervous System
    • Immunology
    • Infectious Diseases
    • Oncology
    • Respiratory

Most Read

  • AstraZeneca divests Atacand commercial rights to Cheplapharm
  • Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
  • AstraZeneca’s heart failure treatment Forxiga gets approval in Japan

Most Recent

deal

AstraZeneca divests Atacand commercial rights to Cheplapharm

05 Jan 2021
Latest Cardiovascular
  • AstraZeneca divests Atacand commercial rights to Cheplapharm
    1 week
  • Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
    3 weeks
  • AstraZeneca’s heart failure treatment Forxiga gets approval in Japan
    2 months
  • AHA 2020: STRENGTH and OMEMI trials show no cardiovascular benefit derived from omega-3 fatty acid…
    2 months
  • AstraZeneca divests Atacand commercial rights to Cheplapharm
    1 week
  • Takeda to divest non-core assets to Hasten Biopharmaceutic for $322m
    3 weeks
  • AstraZeneca’s heart failure treatment Forxiga gets approval in Japan
    2 months
  • AHA 2020: STRENGTH and OMEMI trials show no cardiovascular benefit derived from omega-3 fatty acid…
    2 months
AstraZeneca divests Atacand commercial rights to Cheplapharm
deal

AstraZeneca divests Atacand commercial rights to Cheplapharm

AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to…

05 Jan 2021

Top 5 Most Read

Sponsored 4 hours

A standard approach to drug development for accessing the globe

1
Analysis 1 day

Genomics and Covid-19: UK’s real-time surveillance system to track viral mutations

2
Analysis 2 days

Disease-cancelling drugs: Immuneering raises $62m in Series B round

3
Analysis 3 days

Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020

4
Sponsored 4 days

How much are your pharmaceutical shipments really costing you?

5

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more